These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 16304854)

  • 21. Comparison of effect of locally available brands of clopidogrel on platelet aggregation in patients with coronary artery disease.
    Khan SB; Hameedullah ; Noor L; Hafeezullah M; Awan ZA; ud Din S
    J Ayub Med Coll Abbottabad; 2010; 22(1):115-7. PubMed ID: 21409920
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of antiplatelet efficacy and tolerability of clopidogrel napadisilate with clopidogrel bisulfate in coronary artery disease patients after percutaneous coronary intervention: a prospective, multicenter, randomized, open-label, phase IV, noninferiority trial.
    Park JB; Koo BK; Choi WG; Kim SY; Park J; Kwan J; Park CG; Kim HS
    Clin Ther; 2013 Jan; 35(1):28-37.e4. PubMed ID: 23328268
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-blind, 30-day trial.
    Serebruany VL; Malinin AI; Pokov AN; Hanley DF
    Clin Ther; 2008 Feb; 30(2):249-59. PubMed ID: 18343263
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Single-dose pharmacodynamics of clopidogrel.
    Thebault JJ; Kieffer G; Cariou R
    Semin Thromb Hemost; 1999; 25 Suppl 2():3-8. PubMed ID: 10440415
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of statins on platelet inhibition by a high loading dose of clopidogrel.
    Müller I; Besta F; Schulz C; Li Z; Massberg S; Gawaz M
    Circulation; 2003 Nov; 108(18):2195-7. PubMed ID: 14568892
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Week-long high-maintenance dose clopidogrel regimen achieves better platelet aggregation inhibition than a standard loading dose before percutaneous coronary intervention: results of a double-blind, randomized clinical trial.
    Nguyen TA; Lordkipanidzé M; Diodati JG; Palisaitis DA; Schampaert E; Turgeon J; Pharand C
    J Interv Cardiol; 2009 Aug; 22(4):368-77. PubMed ID: 19689661
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetic and pharmacodynamic effects of elinogrel: results of the platelet function substudy from the intravenous and oral administration of elinogrel to evaluate tolerability and efficacy in nonurgent percutaneous coronary intervention patients (INNOVATE-PCI) trial.
    Angiolillo DJ; Welsh RC; Trenk D; Neumann FJ; Conley PB; McClure MW; Stephens G; Kochman J; Jennings LK; Gurbel PA; Wójcik J; Dabrowski M; Saucedo JF; Stumpf J; Buerke M; Broderick S; Harrington RA; Rao SV
    Circ Cardiovasc Interv; 2012 Jun; 5(3):347-56. PubMed ID: 22619259
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluating the bioequivalence of clopidogrel generic formulations.
    Tsoumani ME; Ntalas IV; Goudevenos JA; Tselepis AD
    Curr Med Res Opin; 2015 May; 31(5):861-4. PubMed ID: 25764150
    [No Abstract]   [Full Text] [Related]  

  • 29. Combination antiplatelet therapy with aspirin and clopidogrel: the role of antecedent and concomitant doses of aspirin. An analysis of 711 patients.
    Serebruany VL; Malinin AI; Atar D
    Cardiology; 2007; 107(4):307-12. PubMed ID: 17264511
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Platelet reactivity after receiving clopidogrel compared with ticagrelor in patients with kidney failure treated with hemodialysis: a randomized crossover study.
    Jeong KH; Cho JH; Woo JS; Kim JB; Kim WS; Lee TW; Kim KS; Ihm CG; Kim W
    Am J Kidney Dis; 2015 Jun; 65(6):916-24. PubMed ID: 25622774
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.
    Storey RF; Husted S; Harrington RA; Heptinstall S; Wilcox RG; Peters G; Wickens M; Emanuelsson H; Gurbel P; Grande P; Cannon CP
    J Am Coll Cardiol; 2007 Nov; 50(19):1852-6. PubMed ID: 17980251
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of smoking on antiplatelet effect of clopidogrel and prasugrel after loading dose and on maintenance therapy.
    Hochholzer W; Trenk D; Mega JL; Morath T; Stratz C; Valina CM; O'Donoghue ML; Bernlochner I; Contant CF; Guo J; Sabatine MS; Schömig A; Neumann FJ; Kastrati A; Wiviott SD; Sibbing D
    Am Heart J; 2011 Sep; 162(3):518-26.e5. PubMed ID: 21884870
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clopidogrel loading dose regimens: kinetic profile of pharmacodynamic response in healthy subjects.
    Savcic M; Hauert J; Bachmann F; Wyld PJ; Geudelin B; Cariou R
    Semin Thromb Hemost; 1999; 25 Suppl 2():15-9. PubMed ID: 10440417
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin.
    Husted S; Emanuelsson H; Heptinstall S; Sandset PM; Wickens M; Peters G
    Eur Heart J; 2006 May; 27(9):1038-47. PubMed ID: 16476694
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized, double-blind comparison of effects of abiciximab bolus only vs. on-label regimen on ex vivo inhibition of platelet aggregation in responders to clopidogrel undergoing coronary stenting.
    Valgimigli M; Campo G; Tebaldi M; Monti M; Gambetti S; Scalone A; Parrinello G; Ferrari R;
    J Thromb Haemost; 2010 Sep; 8(9):1903-11. PubMed ID: 20586923
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Repeated-dose pharmacodynamics of clopidogrel in healthy subjects.
    Thebault JJ; Kieffer G; Lowe GD; Nimmo WS; Cariou R
    Semin Thromb Hemost; 1999; 25 Suppl 2():9-14. PubMed ID: 10440416
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention.
    Hochholzer W; Trenk D; Frundi D; Blanke P; Fischer B; Andris K; Bestehorn HP; Büttner HJ; Neumann FJ
    Circulation; 2005 May; 111(20):2560-4. PubMed ID: 15809367
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clopidogrel generic formulations in the era of new antiplatelets: a systematic review.
    Tsoumani ME; Kalantzi KI; Goudevenos IA; Tselepis AD
    Curr Vasc Pharmacol; 2014; 12(5):766-77. PubMed ID: 23885646
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial.
    ; Alexander JH; Becker RC; Bhatt DL; Cools F; Crea F; Dellborg M; Fox KA; Goodman SG; Harrington RA; Huber K; Husted S; Lewis BS; Lopez-Sendon J; Mohan P; Montalescot G; Ruda M; Ruzyllo W; Verheugt F; Wallentin L
    Circulation; 2009 Jun; 119(22):2877-85. PubMed ID: 19470889
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Withdrawal of two generic clopidogrel products in Saudi Arabia for non-bio-equivalence.
    Alsultan AS; Hakeam HA
    Ann Saudi Med; 2018; 38(3):233-234. PubMed ID: 29848943
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.